MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
XOMA stock logo

XOMA

XOMA Royalty Corp.

$40.17
0
 (0%)
Exchange:  NASDAQ
Market Cap:  503.772M
Shares Outstanding:  10.674M
Delayed data
Calculate XOMA Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Owen Hughes Jr.
Full Time Employees:  14
Address: 
2200 Powell Street
EmeryVille
CA
94608
US
Website:  https://www.xoma.com
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/03/18 — Q4 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue4,75828,48752,149
Gross Profit4,61528,28149,177
EBITDA-22,563-5,42347,818
Operating Income-41,848-39,97611,384
Net Income-40,831-13,82131,712

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets234,301221,277272,698
Total Liabilities145,580139,356168,738
Total Stockholders Equity88,72181,921103,960
Total Debt124,450119,198131,555
Cash and Cash Equivalents153,290101,65482,908

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-18,158-13,7482,871
Capital Expenditure-17-200
Free Cash Flow-18,175-13,7682,871
Net Income-40,831-13,82131,712
Net Change in Cash101,724-53,13427,294

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)79,350Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)79,350Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)79,350Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-13,340.045Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-13,340.045Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-13,340.045Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)22,477.501Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)22,477.501Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)22,477.501Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)190,425.868Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)190,425.868Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)190,425.868Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.250Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.250Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.250Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
28.487M  ?P/S
 (TTM)
: 
13.9
?Net Income
 (TTM)
: 
-13821000  ?P/E
 (TTM)
: 
24.35
?Enterprise Value
 (TTM)
: 
534.042M  ?EV/FCF
 (TTM)
: 
80.5
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
17.54%
?ROE
 (TTM)
: 
30.21%  ?ROIC
 (TTM)
: 
1.94%
?Net Debt
 (TTM)
: 
12.685M  ?Debt/Equity
 (TTM)
: 
1.1
?P/B
 (TTM)
: 
4.23  ?Current Ratio
 (TTM)
: 
3.59

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
45.13Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about XOMA valuation

Is XOMA Royalty Corp. (XOMA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for XOMA Royalty Corp. (XOMA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is XOMA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether XOMA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is XOMA’s P/E ratio?

You can see XOMA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for XOMA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is XOMA a good long-term investment?

Whether XOMA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

XOMA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MARKETSnap

Trading Metrics:

Open: 43.53   Previous Close: 40.17
Day Low: 39.87   Day High: 43.53
Year Low: 22.29   Year High: 45.22
Price Avg 50: 41.95   Price Avg 200: 33.57
Volume: 0   Average Volume: 327501

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
26-08-2026 13:02
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
12-06-2026 16:05
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
Saying Goodbye To The XOMA Royalty PFDs
25-05-2026 08:00
Saying Goodbye To The XOMA Royalty PFDs
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
28-04-2026 12:45
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
27-04-2026 13:18
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read